Adjuvant

Adjuvant Pembrolizumab Improves Secondary Efficacy End Points in RCC

Toni K. Choueiri, MD, discusses results from the KEYNOTE-564 efficacy analysis of adjuvant pembrolizumab in renal cell carcinoma. read more

Lynparza receives Health Canada approval as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer

Health Canada has granted a Notice of Compliance with Conditions (NOC/c) for Lynparza® (olaparib) for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline ... read more

Endocrine Therapy Provides 20-Year Benefit in ER+ Breast Cancer

Two years of adjuvant endocrine therapy in premenopausal patients with ER+ breast cancer can reduce the risk of recurrence at 20 years, research suggests. read more

New Data Bolster Atezolizumab as Adjuvant Tx in NSCLC

A new analysis from IMpower010, presented at the World Conference on Lung Cancer, showed a hazard ratio of 0.71 (95% CI 0.49-1.03) for all-cause mortality with the PD-L1 targeted agent versus best ... read more

Adjuvant medical therapy in cervical dystonia after deep brain stimulation: A retrospective analysis

Results: Nine patients were identified with a mean follow-up of 41.7 ± 15.7 months. All patients continued adjuvant oral medication(s) to optimize symptom control post-operatively. Three stopped BoNT ... read more

Agricultural Spray Adjuvant Market 2022 Top Leading Players, Size Estimation, Growth Factor, Future Trends, Drivers and Forecast to 2028

Global “Agricultural Spray Adjuvant Market” 2022 report includes business strategies, share by application, global ... read more

Ambitious For A Sustainable Future Co-Creation For Innovation

The Kao Corporation of Japan has been committed to improving society for more than 130 years. It began as a soap maker and developed its precise interfacial control technology, which it has applied to ... read more

EC Approves Additional Indication for Lynparza as Adjuvant Treatment in Breast Cancer

The European Commission has approved AstraZeneca and Merck’s Lynparza (olaparib) as an adjuvant treatment for BRCA-mutated HER2-negative high-risk early breast cancer. read more

Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat

Puma Biotech (PBYI) beats earnings and revenue estimates in second-quarter 2022. PBYI's stock surges at market close following the news. read more

LYNPARZA® (olaparib) Approved in the EU as Adjuvant Treatment for Patients With Germline BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer

LYNPARZA as adjuvant treatment can significantly reduce the risk of disease recurrence and death, reinforcing the importance of conducting germline BRCA testing as soon as possible after diagnosis." ... read more